Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 75 versus RENO 60.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 75 versus RENO 60.
HYPAQUE-M,75% vs RENO-60
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
RENO-60 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolality iodinated contrast agent. It attenuates X-rays by blocking photons due to the high atomic number of iodine, thereby enhancing vascular and tissue contrast. It distributes in extracellular fluid and is excreted unchanged by glomerular filtration.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
Intravenous administration of 0.5-1.0 mL/kg (up to 150 mL total) per radiographic procedure. Dose may be repeated once if needed.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Terminal elimination half-life approximately 30-60 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Primarily renal excretion via glomerular filtration; up to 20% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent